Another prominent GLP‐1 RA is semaglutide (Ozempic for T2DM and Wegovy for obesity), which has gained popularity due to its potent effects on both glycemic control and weight reduction. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.